December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Effect of 0.03% Bimatoprost on Patients Non-responders to 0.005% Latanoprost: A Cross-over Study
Author Affiliations & Notes
  • SA Gandolfi
    Ophthalmology University of Parma Parma Italy
  • L Cimino
    Ophthalmology University of Parma Parma Italy
  • Footnotes
    Commercial Relationships   S.A. Gandolfi, None; L. Cimino, None. Grant Identification: Support: MIUR, FIL2000
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 3408. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      SA Gandolfi, L Cimino; Effect of 0.03% Bimatoprost on Patients Non-responders to 0.005% Latanoprost: A Cross-over Study . Invest. Ophthalmol. Vis. Sci. 2002;43(13):3408.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose:to test the efficacy of 0.03% bimatoprost QD in patients affected by ocular hypertension or primary open angle glaucoma and showing no response to 0.005% latanoprost QD Methods:prospective, randomised clinical trial with a cross-over design (two 30-day treatment phases with a 30-day washout phase in between). Random allocation to treatment to one eye only of every patient . n = 15 patients enrolled (5 Primary open angle glaucomas and 10 ocular hypertensives). Eligibility criteria: (a) IOP ≷ 22 mmHg in both eyes on current treatment (on three separate readings ≷ 24 hrs apart ) (b) angle wide open in both eyes (c) no pseudoexfoliation and/or pigment dispersion in both eyes (d) documented medical history consistent with < 10% IOP decrease in both eyes upon a 2 month-treatment with latanoprost 0.005% QD. The following variables were measured at each study visit: (a) IOP (Goldmann applanation tonometry, 5 readings, 8am, 12noon, 4pm, 8pm and 12midnight); (b) visual acuity (ETDRS chart, LogMAR); (c) estimate of conjunctival hyperemia based on 5 standard photographs, (graded as «none», «trace», «mild», «moderate» and «severe»). Main outcome: intra ocular pressure Results:IOP data (mean and standards deviation) were the following: baseline ( after washout) = 24.7 + 0.9 mmHg, after 30 days with latanoprost = 24.1+ 0.9 mmHg, after 30 days with bimatoprost = 18.1+ 1.7 mmHg. IOP upon bimatoprost proved lower than both baseline (p 20% IOP decrease with bimatoprost treatment. None of the 15 patients showed a ≷ 20% decrease of IOP after 30 days of latanoprost treatment. No significant IOP changes were observed in the fellow untreated eye in each patient through the study. Trace-to-mild conjunctival hyperemia was recorded more often with bimatoprost phase ( p = 0.035). Conclusion:patients non-responders to latanoprost 0.005% QD could be successfully treated with bimatoprost 0.03% QD. Bimatoprost treatment was associated with a higher incidence of trace-to-mild conjunctival hyperemia than latanoprost

Keywords: 514 pharmacology • 357 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.